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Paclitaxel is an important chemotherapeutic agent for breast cancer. Paclitaxel has high affinity for the P-glycoprotein (P-gp) (drug
efflux pump) in the gastrointestinal tract causing low and variable oral bioavailability. Previously, we demonstrated that oral paclitaxel
plus the P-gp inhibitor ciclosporin (CsA) is safe and results in adequate exposure to paclitaxel. This study evaluates the activity,
toxicity and pharmacokinetics of paclitaxel combined with CsA in breast cancer patients. Patients with measurable metastatic breast
cancer were given oral paclitaxel 90mgm
 2 combined with CsA 10mgkg
 1 (30min prior to each paclitaxel administration) twice on
one day, each week. Twenty-nine patients with a median age of 50 years were entered. All patients had received prior treatments, 25
had received prior anthracycline-containing chemotherapy and 19 had three or more metastatic sites. Total number of weekly
administrations was 442 (median: 15/patient) and dose intensity of 97mgm
 2week
 1. Most patients needed treatment delay and 17
patients needed dose reductions. In intention to treat analysis, the overall response rate was 52%, the median time to progression
was 6.5 months and overall survival was 16 months. The pharmacokinetics revealed moderate inter- and low intrapatient variability.
Weekly oral paclitaxel, combined with CsA, is active in patients with advanced breast cancer.
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As the incidence of breast cancer rises with advancing age, the total
number of women with breast cancer will increase (Feigelson et al,
1997). Paclitaxel is widely used in advanced breast, lung and
ovarian cancer. In breast cancer, paclitaxel has demonstrated
activity as a single agent in first- and second-line treatment and in
combination schedules (Van Poznak et al, 2002). Tumour response
rates of 20–30% have been observed in several phase III studies in
second-line treatment (Di Leo and Piccart, 1999). Weekly infusions
of paclitaxel have gained wide popularity because of the favourable
toxicity profile allowing dose intensifications (Seidman et al, 1997;
Perez et al, 2001). Seidman et al (1997) reported in a phase II study
using weekly 100mgm
 2 an overall response rate (ORR) of 53% in
30 breast cancer patients who had failed first-line chemotherapy
(Perez et al, 2001). Therapy was well tolerated and remarkable for
a lack of overall and cumulative myelosuppression. Grade 3
sensory neuropathy was observed in 10% of patients receiving
doses of less than 100mgm
 2 per weekly cycle (Seidman et al,
1997). Other phase II studies have confirmed response rates
between 50 and 68% and a favourable safety profile of doses in the
range of 80–100mgm
 2 per weekly cycle in first-line treatment of
advanced breast cancer (Bernard-Marty et al, 2003; Nisman et al,
2003; Sato et al, 2003; Sledge et al, 2003; Toyama et al, 2003).
However, it remains controversial what the optimal dose and
schedule is. Sikov et al recently reported that a weekly schedule of
80mgm
 2 intravenous (i.v.) induced less toxicity than higher
weekly doses of 150mgm
 2 weekly 6 q8wks and 175mgm
 2
weekly 2 q3wks (Green et al, 2005). There is also evidence that
weekly paclitaxel can be effective as rescue in patients who have
failed paclitaxel administered every 3 weeks (Perez et al, 2001).
Oral administration of paclitaxel is convenient and practical for
patients and circumvents systemic exposure to the vehicle
Cremophor EL, which is held responsible for hypersensitivity
reactions (Meerum Terwogt et al, 1998). Moreover, oral admin-
istration enables the development of chronic treatment schedules,
resulting in sustained plasma concentrations above a pharmaco-
logically relevant threshold level. Preclinical studies have shown
that oral bioavailability of paclitaxel is low due to its affinity for the
membrane-bound drug efflux pump P-glycoprotein (P-gp) in the
gastrointestinal tract. The primary routes of paclitaxel presystemic
extraction and elimination consist of successive hydroxy-
lation reactions mediated by the cytochrome P450 CYP2C8
(mainly), CYP3A4 and CYP3A5 isoforms (Sparreboom et al, 1997;
Sparreboom and Verweij, 2003). Preclinical and clinical studies in
our institute have shown that coadministration of oral ciclosporin
(CsA), an efficacious inhibitor of P-gp as well as of CYP3A4-
mediated drug metabolism, results in an approximately eightfold
increase in the systemic exposure to oral paclitaxel. Inhibition of
CYP3A4 may play a role in the increased bioavailability of
paclitaxel, but the bioavailability increased from 4% without CsA
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sto 47% with CsA (Meerum Terwogt et al, 1998; van Asperen et al,
1998; Meerum Terwogt et al, 1999). Another study revealed that P-
gp inhibition by CsA was maximal at a single dose of 10mgkg
 1
(Malingre et al, 2001b). Other paclitaxel formulation, based on an
albumin-stabilised nanoparticle, has also the ability to circumvent
the systemic exposure to Cremophor EL. This compound,
Abraxane
s, is effective in anthracycline-pretreated metastatic
breast cancer patients and has been approved by the FDA for
this indication (www.fda.gov/cder/foi/label/2005/021660lbl.pdf).
In order to improve and prolong the systemic exposure to oral
paclitaxel, a two administrations on one-day schedule was
investigated in a phase I study. We demonstrated that oral
paclitaxel, at the dose level of 90mgm
 2 twice, reached the highest
systemic exposure with a good safety profile (Malingre et al,
2001a). With these issues in mind, we initiated a phase II and
pharmacological study with the combination of oral paclitaxel and
oral CsA twice on one day each week in patients with advanced
breast cancer, previously treated with anthracycline-containing
chemotherapy. Our primary objective was to evaluate the
antitumour activity of this schedule, measured by frequency of
objective response and time to progression, in patients with
recurrent or metastatic breast cancer. The secondary objectives
were the toxicity, overall survival and the pharmacokinetics of the
combination.
PATIENTS AND METHODS
Eligibility criteria
Patients with histologically confirmed, advanced breast cancer
were eligible for this study. Prior chemotherapy, radiotherapy or
hormonal therapy was allowed, but had to be discontinued for at
least 4 weeks prior to study entry. All patients had to have WHO
performance status p2 and should have received a prior
anthracycline-containing chemotherapy. A maximum of two prior
chemotherapy regimens, one of which given for metastatic disease,
was allowed. Prior taxane therapy was not allowed. At entry,
patients were required to have measurable disease according to the
RECIST criteria (Tsuchida and Therasse, 2001). They had to have
adequate haematological, renal and hepatic functions (absolute
neutrophil count (ANC)41.5 10
9l
 1, platelets4100 10
9l
 1,
bilirubinp1.5 times upper limit of normal (ULN), AST and/or
ALT p2.0 ULN, but in the presence of liver metastases p5.0 ULN;
serum creatinine p2.0 times ULN). Exclusion criteria were as
follows: concomitant use of known P-gp inhibitors and chronic use
of H2-receptor antagonists or proton pump inhibitors; known
history of cerebral or leptomeningeal metastases; history of prior
malignancy, except completely excised in situ carcinoma of the
cervix or nonmelanoma skin cancer; bowel obstruction or motility
disorders that could influence the absorption of drugs; con-
current treatment with other experimental drugs; allergy to CsA;
concomitant medication which has been reported to increase the
metabolism of CsA; serious concurrent disease; unresolved
toxicities of previous treatment (Xgrade 2); angina or myocardial
infarction in the 6 months prior to study entry; and second or third
degree AV block without pacemaker, or congestive heart failure.
The study protocol was approved by the Medical Ethics
Committees of all five participating institutes (see Acknowl-
edgments) and all patients gave written informed consent.
Treatment plan
On day 1 of each week, oral paclitaxel (Paxoral
s, IVAX research,
Inc. Miami, USA) was administrated twice (90mgm
 2 2) with at
least seven, but not more than 12h dose interval. Ciclosporin in a
dose of 10mgkg
 1 was given 30min prior to each dose of oral
paclitaxel. Ciclosporin (Neoral
s, Novartis, Basel, Switzerland) was
supplied as capsules of 50 and 100mg, or as a liquid solution of
100mgml
 1. Oral paclitaxel was supplied as a solution of
12mgml
 1 in a bottle. For further information about the oral
administration and dietary advise, see our previous publication
(Kruijtzer et al, 2003). Our previous phase I studies revealed that
antiallergic premedication (dexamethasone, clemastine, ranitidine)
could be omitted (Malingre et al, 2000). Only oral granisetron was
given 1h prior to intake of the chemotherapy to prevent nausea
and vomiting. This treatment was administered weekly until
disease progression or unacceptable toxicity developed.
Evaluation of response
Standard clinical measurements and radiological examinations
were used to ensure measurable disease according to RECIST
(Tsuchida and Therasse, 2001) criteria for response evaluation.
Radiologic responses were confirmed by independent external
radiologic reviews. Patients who completed at least 6 weekly cycles
were considered evaluable for response. The primary end point of
the study was response rate. We also determined the duration of
response, which was defined as the number of days between the
onset of response and the date of last progression-free evaluation.
Response was determined every 6 weeks. For patients who had not
progressed the date of last progression-free evaluation would be
censored. We determined the time to progression as the number of
days between the date of first treatment and the date on which
progression was clearly documented, or death had occurred.
Evaluation of toxicity
Pretreatment evaluation included a complete medical history and
complete physical examination. Haematology and blood chemi-
stries were checked prior to treatment and subsequently weekly.
All toxicities were weekly graded according to the National Cancer
Institute Common Toxicity Criteria (NCI-CTC, v.2.0 http://
ctep.cancer.gov). All patients who received at least one weekly
cycle of therapy were evaluable for toxicity. In case of toxicity,
two dose reductions were allowed: first to 70mgm
 2 (twice) and
then to 55mgm
 2 (twice) or 90mgm
 2 (once) if the patient
experienced persistent nausea or vomiting after the morning
administration. Patients, who required further dose reductions,
were withdrawn from the study. Nonhaematological toxicity of
grade 3 or 4 (except inadequately treated nausea and vomiting) or
haematological toxicity consisting of ANC of o0.5 10
9l
 1, and
neutropenic fever or thrombocytopenia o25 10
9l
 1 was man-
dated for dose reduction of one dose level. For patients who
required dose reductions, the dosage was not re-escalated in
subsequent cycles. Treatment was postponed until recovery of
thrombocytes 4100 10
9l
 1 and neutrophils 41.5 10
9l
 1. The
CsA dose of 10mgkg
 1 remained constant.
Sample collection and analysis
Pharmacokinetic monitoring was performed during the first two
weekly cycles. For paclitaxel, blood samples of 5ml were collected
in heparinised tubes, at 0, 30 and 60min and at 2, 3, 4, 6, 7, 7.5, 8,
10, 12, 24 and 30h after ingestion of paclitaxel. For further
information on sample collection and paclitaxel analysis, see
previous publication (Kruijtzer et al, 2003).
Pharmacokinetic analysis
A population pharmacokinetic model was developed for paclitaxel
by using the nonlinear mixed-effect modelling program NONMEM
(double precision; version V, level 1.1) as published previously
(Kruijtzer et al, 2003). Briefly, the first-order conditional estima-
tion method was applied. A two-compartment structural kinetic
model with first-order absorption and elimination and saturable
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stransport between central and peripheral compartment was used to
describe the time profiles of paclitaxel plasma concentration. The
pharmacokinetics of paclitaxel were parameterised in terms of
absorption rate constant (Ka), volume of distribution of the central
compartment (V), clearance from the central compartment (CL),
maximal transport capacity from the central to the peripheral
compartment (TRmax), the concentration at which the transport is
half-maximal (TRm) and rate constant for transport form the
peripheral to the central compartment (k21). Since paclitaxel was
administered orally, the plasma terms ‘volume of distribution’,
‘clearance’ and ‘maximal transport capacity’ represent the ratio of
these parameters (V, CL, TRmax) to the unknown bioavailability.
Individual pharmacokinetic parameters were estimated by
Bayesian approach. On the basis of these parameters, individual
plasma concentration–time profiles were generated for the
assessment of the area under the plasma concentration–time
curve (AUC), the maximal plasma concentration (Cmax), the time
to maximal plasma concentration (Tmax) and the time above the
previously defined threshold concentrations of 0.1mM (T40.1mM)
and 0.05mM (T40.05mM). The values of Tmax and Cmax were
directly determined from the experimental data. For CsA, the AUC
was determined according to the trapezoidal method by Phar-
sight
s WinNonlint, ed. 5.0.1.
Statistics
Patients were accrued according to a two-stage design (Simon,
1989) aiming at 25 eligible patients. Analyses of response rate and
time to progression were performed on all evaluable patients and
on the total population. The time to progression and overall
survival curves were estimated using the Kaplan–Meier method.
RESULTS
Patients and characteristics
In total, 29 patients were recruited between November 2000 and
February 2003 in four cancer centres (The Netherlands Cancer
Institute, Amsterdam, The Netherlands; Innere Universita ¨tsklinik
und Poliklinik, Essen, Germany; Kliniken St Antonius, Wuppertal,
Germany; and Ashford Cancer Centre, Ashford, Australia (23, 3, 2
and 1 patients, respectively) in this study. Four patients were not
eligible: three because of lack of previous anthracycline-containing
chemotherapy and one did not meet the RECIST criteria for
evaluation. Response evaluation was not formally possible in two
patients according to the definition of the protocol, in one patient
because of disease progression after two administrations and one
patient was lost to follow-up after the first paclitaxel administra-
tion. All, except one (lost to follow-up), were eligible for toxicity
evaluation. Table 1 lists the clinical characteristics of all patients.
Median age was 50 years (range 34–66 years) and all, except one
patient, were postmenopausal at the start of study treatment.
Eighteen (62%) had oestrogen- and/or progesterone-positive
tumour. Twenty-six (90%) patients had more than one metastatic
site, mostly bone (69%), liver (62%) and lymph node metastases
(55%). Of 23 evaluable patients, nine (39%) received prior
adjuvant anthracycline chemotherapy, 14 (61%) received prior
palliative anthracycline chemotherapy and three patients received
prior two (anthracycline plus CMF (2) or vinorelbine (1))
treatment lines. Of evaluable patients, 15 (65%) received prior
antihormonal therapy, five as adjuvant treatment, 10 as palliative
(range 1–4) treatment and four patients received both adjuvant
and palliative antihormonal therapy.
Dose intensity and dose reduction
Twenty-nine patients received in total 442 weekly oral paclitaxel
and CsA administrations with a median of 15 (range 1–36) per
patient. Of those 442 administrations, 299 (68%) were two doses
and 143 (32%) were in one dose because of nausea and vomiting in
seven patients (24%) after the morning dose. Of the 299
administrations, 191 (64%) were given according to the standard
dose of 90mgm
 2, and 87 (29%) and 21 (7%) at the reduced dose
of 70 and 55mgm
 2, respectively. Of the 143 administrations, 87
were given at a dose of 90mgm
 2, and 21 and 35 at the reduced
dose of 70 and 55mgm
 2, respectively. Overall, the median dose
intensity was 97mgm
 2week
 1 (range 52.4–180mgm
 2week
 1).
One patient received only one intake of paclitaxel and refused
thereafter further treatment. Seventeen patients needed dose
reductions, mostly (59%) because of moderate neutropenia, which
did not resolve within 1 week of delay, or nausea and vomiting
after the morning intake. Twenty-six patients experienced treat-
ment delay of in total 234 weekly administrations, median 8 (range
0–38), mostly because of grade 3–4 neutropenia.
Response
Antitumour activity of paclitaxel combined with CsA was evaluable
in twenty-three patients (Table 2). There were no complete
responses. Partial response, for more than 12 weeks, was seen in
Table 1 Patient characteristics
Patients (ITT) Patients
Character All (n¼29) % Evaluable (n¼23) %
Age (years)
Median (range) 50 (34–66) 48 (34–65)
Menopausal status
Premenopausal 1 1
Postmenopausal 28 22
Hormonal receptor status
Positive 18 62
Negative 9 31
Unknown 2 7
Prior treatment
Chemotherapy 26 90 23 100
Anthracycline containing 25 86 23
Antihormonal therapy 19 65 15 65
Radiotherapy 17 59 15 65
Surgery 14 48 12 52
Previous anthracycline
Adjuvant 10 34 9 39
Palliative 15 52 14 61
Prior chemotherapy lines
12 1 7 3 2 0 8 7
2 5 17 3 13
Sites of metastases
Bones 20 69 16 70
Liver 18 62 15 65
Lymph nodes 16 55 12 52
Lungs 10 35 6 26
Contralateral breast 8 28 7 30
Skin 5 17 4 17
Pleura 4 14 3 13
Spleen 1 3 1 3
No. of metastatic sites
Two or more 26 90 20 87
Three more 19 65 14 61
Four or more 6 21 4 17
ITT, intention to treat.
Paxoral in woman with advanced breast cancer
HH Helgason et al
796
British Journal of Cancer (2006) 95(7), 794–800 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s15 patients, resulting in an ORR of 51.7% (95% confidence interval
(CI), 33.5–69.9%) in all 29 patients and 65.2% (95% CI, 45.7–
84.7%) in all 23 for response-evaluable patients. Four other
patients had disease stabilisation, for more than 12 weeks,
resulting in meaningful disease stabilisation (partial response or
stable disease) in 65.5% of all patients and 82.6% of response-
evaluable patients. Four of the response-evaluable patients (17.4%)
had progressive disease at the time of first evaluation after 6
weekly administrations.
Treatment duration
As of December 2003, all patients have discontinued treatment. Of
the 15 patients who had an initially confirmed partial response, 10
patients later discontinued treatment as a result of disease
progression after, respectively, 25–45 (mean 34) and 14–36 (mean
23) weeks administrations. Four patients discontinued treatment
because of toxicity after, respectively, 6, 8, 11 and 28 weekly
administrations. One patient was lost to follow-up after 17 weekly
administrations. Two patients with disease stabilisation stopped
because of disease progression after, respectively, 16 and 18 weeks
of treatment. Two other patients stopped because toxicity (grade 4
myelosuppression, grade 2 nausea and vomiting) developed after
16 weeks of treatment and, respectively, 7 and 11 weekly
administrations. The patient who stopped because of grade 4
myelosuppression was treated with weekly paclitaxel i.v. for
another 12 weeks before disease progression. Four patients
stopped after first evaluation after six administrations because of
progressive disease. Of the six patients who were not formally
evaluable for response, two patients discontinued treatment
because of toxicity after, respectively, 13 and 15 weekly adminis-
trations, two patients discontinued treatment because of disease
progression after, respectively, 2 and 33 weekly administrations,
one was lost to follow-up after eight administrations and one
refused further treatment after one single intake and is lost to
follow-up.
Time to progression and overall survival
As of December 2003, the median time to progression was 6.5
months (95% CI, 4–10) in evaluable patients. Of all patients, 16 are
deceased, seven are alive at, respectively, 10.5, 12.5, 12.5, 15.5, 29.5,
32 and 36.5 months after starting treatment and six are lost to
follow-up after, respectively, 0.5, 2, 2.5, 5.5, 10.5 and 19 months
from the start of treatment. Median overall survival was 16 months
(95% CI, 9–24) for all patients. The Kaplan–Meier curve of overall
survival of all patients is shown in Figure 1.
Toxicity
All patients were eligible for toxicity evaluation, except one, who
was lost to follow-up after one administration. Eight (27.6%)
patients had to stop their treatment because of toxicity, mainly
neutropenia (CTC grades 3–4) or nausea and vomiting after
the morning intake, after 6, 7, 8, 11 (two patients), 13, 15 and
28 weeks, respectively. The principal haematological toxicity was
neutropenia, as 15 (54%) patients experienced significant
(CTC grades 3–4) neutropenia (Table 3). However, only three
events of neutropenic fever and no sepsis were observed. Of the
nonhaematological toxicities, gastrointestinal toxicity was most
frequently reported (Table 3). Although there were no grade
3 nausea nor grade 3 or 4 vomiting, these toxicities were important
reasons for dose reductions and change in dose schedule from
twice daily to once daily. Overall grade 1 and 2 nausea and
vomiting were reported in 90 and 75% of patients, respectively.
Twenty (71%) patients reported diarrhoea, mostly grade 1 and 2,
but one patient had diarrhoea grade 3. Serious neurotoxicity
(Xgrade 2), as commonly described for treatment with i.v.
paclitaxel, was seen in five patients (18%) after an average number
of 21 (7–32) administrations. Other toxicities of importance were
asthenia in 16 (two grade 3) patients, fatigue in 21 (six grade 3)
patients, arthralgia/myalgia in 14 (no grade 3) patients and nail
Table 2 Best response to weekly oral paclitaxel in combination with
CsA (after up to 12 weekly administrations)
No. of
patients
(N¼29)
% of evaluable
patients
(N¼23)
%o fI T T
population
(N¼29)
Complete response 0 0 0
Partial response 15 65.2 51.7
Stable disease 4 17.4 13.8
Progressive disease 4 17.4 13.8
Not evaluable 6 20.7
CsA, ciclosporin; ITT, intention to treat.
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Figure 1 Kaplan–Meier curve of time to progression in evaluable
patients (n¼23).
Table 3 Treatment toxicity (N¼28)
1234
Grade N (%) N (%) N (%) N (%) % Grades 3–4
Leucocytopenia 0 5 (18) 13 (46) 2 (7) 53
Neutropenia 0 4 (14) 14 (50) 1 (4) 54
Thrombocytopenia 0 0 0 0
Anaemia 2 (7) 7 (25) 0 0
Alopecia 2 (7) 24 (86)
Nausea 15 (57) 10 (36)
Vomiting 17 (61) 4 (14)
Fatigue 5 (18) 10 (36) 6 (21)
Diarrhoea 13 (46) 6 (21) 1 (4)
Neurotoxicity 11 (39) 5 (18)
Arthralgia/myalgia 13 (46) 3 (11)
Asthenia 3 (11) 11 (39) 1 (4)
Abdominal cramps 6 (21) 5 (18)
Constipation 10 (35) 1 (4)
Nail changes 4 (14) 3 (11)
Worst grade per patient. One patient was lost to follow-up after one administration.
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sabnormalities in seven patients. Possible because of the short
interval between paclitaxel and CsA, we were not able to identify
any short-term adverse effects of CsA, but it may have contributed
to the diarrhoea and neurotoxicity. Renal toxicity was not
observed. There was no grade 4 nonhaematological toxicity and
no toxic deaths.
Pharmacokinetics
Pharmacokinetic analysis was possible in 26 patients covering in
total 50 courses of chemotherapy (26 in week 1 and 24 in week 2).
Several pharmacokinetic models were applied to the data,
including two- and three-compartmental models with linear and/
or saturable distribution and/or elimination. The data were best
described using a two-compartmental model with first-order
absorption, linear elimination and saturable distribution to the
peripheral compartment. The value of TRm (the concentration at
which the transport rate to the peripheral compartment is half-
maximal) could not be estimated and was fixed to a value of
120mgl
 1 (0.14mmoll
 1) as obtained in a previous analysis on oral
application of paclitaxel in patients with gastric cancer (Kruijtzer
et al, 2003). The model-based and Bayesian-predicted concentra-
tions were symmetrically distributed around the line of identity,
indicating the adequacy of the population model (data not shown).
On the basis of individual Bayesian estimates, secondary
pharmacokinetic parameters of two administrations of oral
paclitaxel were derived (Table 4). The mean AUC of orally
administered paclitaxel was 430471426mghl
 1 (5.0471.67mM)i n
week 1 and 400571110mghl
 1 (4.6971.3mM) in week 2. The
calculated interpatient variability (%CV) of the AUC of paclitaxel
was 33.2 and 27.5% in week 1 and 2, respectively. The intrapatient
variability (%CV) of the AUC was only 17.4%. The mean T40.1mM
values were 13.275.1h in week 1 and 12.173.8h in week 2. The
mean T40.05mM values were 23.878.5h in week 1 and 22.477.5h
in week 2. The mean Cmax values after the first and second dose
were comparable in week 1 and 2, but a small increase of the Cmax
value was noted after the second dose.
DISCUSSION
This phase II study with oral paclitaxel combined with CsA, in
anthracycline-pretreated women with metastatic breast cancer
revealed an ORR of 51.7% and overall survival of 16 months. The
ORR in 23 evaluable patients was 65.2% and meaningful disease
stabilisation, for more than 12 weeks, was 82.6%. The median time
to progression was 6.5 months for all evaluable patients. This
response rate lies in the upper range of results of chemotherapy in
breast cancer patients (Di Leo and Piccart, 1999; Nisman et al,
2003; Lombardi et al, 2004b). Three patients were not evaluable
because they had not received previous anthracycline-containing
chemotherapy. One of these patients achieved partial remission for
17 months and another patient achieved disease stabilisation for 9
months. The third patient was lost to follow-up after eight
administrations. Response evaluation was not possible in three
patients. It must be realised that the number of evaluable patients
was limited and consequently the CI is wide.
The toxicity was manageable and consisted mainly of myelo-
suppression, which was neutropenia (CTC grade X2 in 68% of
patients) without morbidity or mortality, moderate anaemia but
no thrombocytopenia. This toxicity pattern is consistent with other
reports of i.v. paclitaxel (Seidman et al, 1997; Di Leo and Piccart,
1999; Lombardi et al, 2004a). Previously, we demonstrated in a
phase I study that a relevant systemic exposure of oral paclitaxel,
with a good safety profile, was reached at the dose level of
90mgm
 2 twice on one day each week (Malingre et al, 2001a). The
current study supports the moderate toxicity of this regimen.
Nausea and vomiting were the most important nonhaematological
toxicities and lead most often to omission of the afternoon
administration and consequently to alteration in the dose schedule
from twice to once daily administration (32% of all weekly
administrations). Nausea was more related to the smell and taste of
the oral paclitaxel liquid solution than to its emetogenic effects.
Recently, we prepared a capsule formulation that may significantly
improve gastrointestinal tolerance to oral paclitaxel. Reversible
sensory polyneuropathy was seen in 16 patients and was CTC
grade 1 in 11 and grade 2 in five patients, respectively. The five
patients with CTC grade 2 polyneuropathy received a median of 21
administrations (range 7–32) at a dose intensity of
105mgm
 2week
 1 and cumulative dose of 3056mg, suggesting
that the cumulative dose of paclitaxel, rather than peak
concentration, is the major determinant of this side effect.
Cremophor EL is not likely to contribute much to this toxicity
as has been shown previously (Mielke et al, 2005b). Moderate
diarrhoea was reported in 20 patients and was mostly easily
manageable.
The mean dose intensity in our study was 97mgm
 2week
 1
(range 52.4–180mgm
 2week
 1), or 54% of the planned dose, and
the mean number of weekly paclitaxel administrations was 15. This
is lower than in our previous reports on weekly oral paclitaxel in
gastric (141mgm
 2week
 1) and non-small-cell lung cancer
(172mgm
 2week
 1) patients (Kruijtzer et al, 2002, 2003). This
can be explained by the shorter treatment duration related to the
shorter time to progression and overall survival in the gastric and
lung cancer patients, compared to breast cancer patients (Kruijtzer
et al, 2002, 2003). The mean dose intensity of 97mgm
 2week
 1 is
higher than reached with the standard 3 weekly i.v. schedule.
However, it is comparable with most weekly i.v. paclitaxel
schedules of 80–100mgm
 2week
 1 in patients with advanced
breast cancer. Direct comparison of pharmacokinetic values and
doses for oral vs i.v. paclitaxel must be made with caution, because
of the nonlinear pharmacokinetic behaviour of i.v. paclitaxel
(Malingre et al, 2000), but the incidence of neutropenia supports
adequate paclitaxel exposure.
Table 4 Pharmacokinetic parameters of twice on one day dosing of oral paclitaxel in 26 patients (data are listed as mean7s.d.)
Cmax AUC
lgl
 1 lmoll
 1 Tmax (h) lghl
 1 h*lmoll
 1 T40.1lmoll
 1 (85.39lgl
 1)( h ) T40.05lmoll
 1 (42.7lgl
 1) (h)
Week 1 4304 (1426) 5.04 (1.67) 13.2 (5.1) 23.8 (8.5)
Dose 1 333 (120) 0.39 (0.14) 1.51 (0.71)
Dose 2 376 (94) 0.44 (0.11) 1.56 (1.50)
Week 2 4005 (1110) 4.69 (1.3) 12.1 (3.8) 22.4 (7.5)
Dose 1 342 (102) 0.40 (0.12) 1.59 (0.80)
Dose 2 376 (120) 0.44 (0.14) 1.29 (0.71)
AUC¼area under the plasma concentration–time curve. The dose of paclitaxel was 90mgm
 2 and the dose of CsA was 10mgkg
 1.
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sMost patients experienced some form of dose reduction.
Twenty-six patients needed a delay of administration with a total
234 delayed weekly cycles of median 8 weeks (range 0–38). This
was mostly because of moderate neutropenia, but occasionally on
patient request. In total, 29 dose reductions were needed in 17
patients, because of neutropenia or neutropenia and nausea, in 10
and seven patients, respectively. Most of these patients, especially
those with nausea, tolerated the once daily dosing better, which
enabled further treatment. One patient with stable disease
developed grade 4 neutropenia and switched to i.v. paclitaxel for
16 weeks before disease progression. Because of dose reductions
approximately 143 administrations (32%) were given once daily.
There were no serious adverse reactions or toxic deaths in our
study. Future studies need to assess a reduced dose to limit
neutropenia allowing continued treatment. Furthermore, should a
capsule formulation of paclitaxel lower the incidence of antici-
patory nausea and vomiting making the treatment more con-
venient. Oral administration of paclitaxel circumvents systemic
exposure to the vehicle Cremophor EL, which compound is
responsible for hypersensitivity reactions, thus enabling us to
avoid pretreatment with H1 and H2 blockers and steroids and their
potential adverse effects (Meerum Terwogt et al, 1998).
Although we cannot exclude some short-term gastrointestinal
adverse effects of CsA, the incidence of nausea was directly related
to the smell or taste of paclitaxel. In concordance to our previous
results, the weekly dose of CsA was not associated with renal
toxicity or infections (Kruijtzer et al, 2002, 2003). This can most
likely be attributed to the weekly administration of the drug, while
after organ transplantation, CsA is administered on a continuous
daily basis. At this dose and schedule, CsA is also not expected to
have important long-term negative effects.
The pharmacokinetic data indicate good reproducibility of
pharmacokinetic parameters of orally administered paclitaxel. The
peak plasma concentration was comparable with our previous
results (Kruijtzer et al, 2002, 2003), but significantly lower than
obtained with the conventional three weekly schedule, which might
have contributed to the low incidence of neurotoxicity, although
the cumulative dose seems to be a major contributing factor to this
toxicity (Huizing et al, 1993; Mielke et al, 2005b). The median time
period of paclitaxel plasma concentration above 0.1mM was 13.2
and 12.1h in week 1 and 2, respectively, which is comparable to
our earlier results (Kruijtzer et al, 2002, 2003), but longer than
obtained with the conventional three weekly schedule if calculated
upon 3-week interval. Population pharmacokinetic analysis
revealed that the pharmacokinetics of orally administered
paclitaxel were best described by a two-compartmental model
with first-order absorption, linear elimination and saturable
distribution to peripheral compartment, as has been shown for
unbound paclitaxel, which supports the opinion that Cremophor
EL is responsible for the nonlinear pharmacokinetics of i.v.
paclitaxel (Henningsson et al, 2003). The pharmacokinetics of i.v.
and by orally administered paclitaxel, with and without Cremo-
phor EL in the systemic circulation, respectively, are substantially
different, which makes further comparison of AUC values,
obtained after oral and i.v. administration, difficult. The known
nonlinear pharmacokinetics of i.v. paclitaxel is due to intra-
vascular paclitaxel entrapment caused by Cremophor EL. Conse-
quently, direct comparison of i.v. and oral paclitaxel could
underestimate the true bioavailability of oral paclitaxel (Malingre
et al, 2001a; Gelderblom et al, 2002; Mielke et al, 2005a).
The calculated interpatient variability of the AUC of paclitaxel
was 33.2 and 27.5% in week 1 and 2, respectively. This variability is
moderate and comparable with the variability of other chemo-
therapy treatments that rely on body surface for dose calculations
(Baker et al, 2002). The intrapatient variability of the AUC was
only 17.4% and indicates a limited variation in the apparent
bioavailability of our formulation of oral paclitaxel with CsA.
Use of oral chemotherapy formulations has significant advan-
tages over classical i.v. treatment. It enables outpatient-based
treatment, at home, with increased patient comfort and possibly
quality of life, but also bi-daily administration resulting in
prolonged paclitaxel exposure with potentially higher activity.
With the absence of plasma Cremophor EL exposure in oral
paclitaxel formulations, we can circumvent the use of antiallergic
medications (Meerum Terwogt et al, 1998). Abraxane
s,a n
albumin-stabilised nanoparticle formulation of paclitaxel, has also
the ability to effectively deliver paclitaxel to the circulation without
Cremophor EL, but has the disadvantage of i.v. use.
A disadvantage of oral formulations of chemotherapy is the
possible interaction with food and comedication and unpredictable
changes in uptake caused by vomiting or diarrhoea. The low
intrapatient variability, as observed in current study, shows that
this is not a problem in case of oral paclitaxel combined with CsA.
The combination is mildly emetogenic and the maximal plasma c
is reached within 1–2h after intake. Future capsule formulations
are expected to reduce gastrointestinal toxicity like nausea,
vomiting and diarrhoea, allowing more comfortable and safe
administration.
Combination of oral paclitaxel with different oral cytotoxic
therapies like vinorelbine or capecitabine or with cytostatic
therapies like thyrosine kinase inhibitors has a clinical potential,
but its safety and activity has to be addressed in future studies.
This study can serve as a template for the oral development of
other drugs that show high affinity for ABC drug transporters and
low and variable oral bioavailability.
In conclusion, this study revealed that weekly administration of
oral paclitaxel, in combination with CsA, is an active and feasible
treatment option for patients with advanced breast cancer who
have received anthracycline-containing chemotherapy. Once daily
dose administration with promising oral capsule formulations
should lead to fewer adverse effects, better tolerance and
compliance, without reduction in paclitaxel exposure and efficacy
against solid malignancies. Current studies focus on testing of new
capsule formulations of oral paclitaxel.
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